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1. Introduction
Peritoneal dialysis (PD) is a form of renal replacement therapy that is growing progressively,
possibly because of the freedom it offers to the patients and the undoubted improvement in
the PD technique. Parallel the PD-related complications have also increased. In PD, the
peritoneal membrane (PM) is exposed to bio-incompatible dialysis solutions, rich in glucose,
which can cause peritoneal injury when associated with peritoneal incidents like repeated
episodes of peritonitis or hemoperitoneum [1]. Progressive fibrosis, angiogenesis and ulti‐
mately, ultrafiltration failure, are some characteristics of the so-called sclerotic peritonitis
syndromes (SPS) [2].
Several pathologic factors, such as inflammatory mediators, high glucose content, the presence
of glucose degradation products, and low pH can induce peritoneal mesothelial cells (MCs)
to lose certain epithelial characteristics, and they progressively acquire a fibroblast-like
phenotype soon after initiation of PD [3]. This so-called mesothelial-to-mesenchymal transition
(MMT) serves as a trigger for peritoneal fibrosis and angiogenesis, via up-regulation of
transforming growth factor-β (TGF-β1 and vascular endothelial growth factor (VEGF),
respectively. As such, MMT is considered an important potential therapeutic target in sclerotic
peritonitis syndromes [4]. Encapsulating peritoneal sclerosis (EPS) is a severe form of perito‐
neal fibrosis characterized by intestinal encapsulation through the formation of excessive
matrix components that subsequently may lead to obstruction of the intestinal tract [5].
Although rare, EPS is a serious complication of PD for which no specific and definitive
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treatment exists [6]. However, peritoneal resting, steroids, immunosuppressive agents and
Tamoxifen have been used previously as therapeutic approaches with divergent results [4].
Herein, we review in detail the effect of PD liquids and other peritoneal accidents like
peritonitis and hemoperitoneum on the MCs physiology, the trandifferentiation in fibroblast-
like cells (MMT), its clinical correlation with data from peritoneal and morphologic function
(peritoneal biopsies), the initiation and perpetuation of peritoneal fibrosis (SPS) and his
eventual rise to EPS. We also purpose therapeutic alternatives, ranging from the improvement
in the biocompatibility of the liquids of DP, the use of drugs available on the market today, or
even the use of molecular strategies, as blockades or stimulation of genes involved in the
peritoneal damage.
2. Morphologic and phenotypic MCs characterization
The mesothelium is a continuous superficial layer of MCs formed by flattened, polygonal,
mononuclear, squamous epithelial cells. This monolayer shows remarkable fibrinolytic
properties and is thought to be involved in the prevention of fibrous adhesion formation in
the peritoneum. MCs cells have vast biosynthetic capacity and secrete phospholipids and
phosphotidylcholine in the form of lamellar bodies that provide a lubricating surface for the
movement of abdominal viscera [7]. Besides this function, the mesothelium also modulates
peritoneal microcirculation by secreting vasodilators (eg, prostaglandin E2 and nitric oxide),
as well as vasoconstrictors (eg, endothelin) [8]. The luminal aspect of MCs plasmalemma has
numerous cytoplasmic extensions called “microvilli” which play a significant role in the
transperitoneal transfer of anionic macromolecules such as proteins. Microvilli are extremely
sensitive and easily lost due to injury [9].
MCs can be isolated from healthy omentum donors of elective abdominal surgeries and the
effluent from patients with PD. The analysis of the effluent drained peritoneal MCs has allowed
us to assess the health status of peritoneal. The purity of effluent and omentum-derived MC
cultures are determined by the expression of standard mesothelial markers: ICAM-1, cytoker‐
atins, and calretinine. MCs cultures remain stable, without any evident sign of senescence, for
at least two to three passages [10, 11].
The analysis of cytokeratins and E-cadherin expression, that are typical epithelial markers and
highly expressed in MC, is important to determine more precisely the nature of effluent-
derived cells. High expression of cytokeratins and E-cadherin is only observed in omentum-
derived MC, whereas effluent-derived cells show a progressive reduction in the expression of
these molecules, although even fibroblast-like MC may maintain a small population of positive
cells (Figure 1). In mixed populations the expression of cytokeratins and E-Cadherin is
normally bimodal. Fibroblasts are completely negative for these two markers. Previous studies
had characterized the cobblestone-like MC from effluents as indistinguishable from omentum-
derived MC. However, already in this early stage a loss of apico-basolateral polarity as well
as down-regulation of cytokeratins and E-Cadherin is observed ex vivo, even though cells still
show a morphologically epithelioid appearance [10-12].
The Latest in Peritoneal Dialysis22
Figure 1. Morphology and gene expression of MCs. Panel “A” shows a culture of MCs isolated from omentum do‐
nor. Cells show the typical cobblestone phenotype. Panel “B” shows MCs isolated from PD effluent with transitional
phenotype, and panel “C” shows a fibroblastoid phenotype these cells were isolated and cultured from the PD efflu‐
ent. The genetic pattern of each phenotype is described below.
The morphological changes and down-regulation of cytokeratin and E-Cadherin in effluent-
derived MC are indicative of an MMT. MMT is a complex and generally reversible process
that starts with the disruption of intercellular junctions and loss of apical–basolateral polarity,
typical of epithelial cells, which are then transformed into fibroblast-like cells with increased
migratory, invasive and fibrogenic features. The objective of this process is to repair tissue
wounds by promoting the recovery of ancestor capabilities of epithelial cells. Cell migration,
production of extracellular matrix and induction of neoangiogenesis are the main activities
[11, 12]. This process is conducted by the transforming growth factor-β (TGF-β) and the
representative cell form is the myofibroblast (Figure 2). TGF-β synthesis may be stimulated by
glucose, and infections, via peritoneal leucocyte-derived factors. TGF-β has been found to be
up-regulated in peritoneal inflammatory processes and its over-expression has been correlated
to worse PD outcomes [13]. Moreover, the injection of an adenovirus vector that transferred
active TGF-β1 in rat and mice peritoneum induces myofibroblastic conversion of MC. [14, 15].
TGF-β is a growth factor that has been implicated as the causal agent in fibrosis of different
tissues and organs [16].
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Figure 2. From a normal peritoneum to a PD peritoneum suffering MMT. Panel “A” shows a normal peritoneun
without fibrosis, angiogenesis or MMT (3D image). Panel “B” shows a PD paritoneum with MCs exposed to PD fluids.
MCs lose their microvilli, suffer MMT and invade submesothelial area, where synthesize VEGF, angiogenesis, prolifera‐
tion, migration and EMC production. Both glucose (GDPs and AGEs) from PD fluids and inflammatory molecules stim‐
ulate TGF-β production which trigger MMT.
3. MMT signalling
Figure 3 shows the signaling cascade of MMT which begins with the activation of TGF-β which
is considered the master molecule in peritoneal injury during PD. Activation of TGF-β
receptors triggers smads-dependent and smads-independent signaling. Smads depending
pathway include integrin-linked kinase, GSK-3, β-catenin, Lef-1/Tcf and AP gene cascade.
Smads independing include RhoAp160ROCK and H-Ras/Raf/ ERK pathways [17-32].
4. Clinical implication of MMT in PM failure
We have described three major morphologies of MCs cultures from PD effluents: cobblestone-
like, similar to omentum-derived MC, transitional and fibroblast-like MC which remained
stable for at least two to three cell passages. After analyzing more than two hundred MC
cultures with growth capacity, from more than 100 PD patients, we determined that the
frequencies of the different effluent-derived MC cultures are approximately 53 percent for
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cobblestone-like, 24 percent for transitional, and 17 percent for fibroblast-like MC. The
prevalence of non-epitheliod MC cultures (transitional or fibroblast-like) is associated with the
time the patients have been subjected to PD and with the episodes of acute or recurrent
peritonitis or hemoperitoneum [3, 10, 11]. We have also described a less frequent (less than 6
percent) cell culture with mixed morphologies [3, 10]. Effluent mesothelial cells were isolated
from 37 PD patients and analyzed for mesenchymal conversion. Mass transfer coefficient for
creatinine (Cr-MTC) was used to evaluate peritoneal function. VEGF concentration was
Figure 3. TGF-β signaling. Glucose, low pH from PD fluids, advanced glycation end products (AGEs), glucose degrada‐
tion products (GDPs), peritonitis and haemoperitoneum stimulate TGF-β synthesis, and possibly FGF which in turn trig‐
gers the healing processes that ultimately lead to tissue fibrosis and angiogenesis. The increase in total VEGF
production might increase the VEGF-C levels, which are directly implicated in lymphogenesis. TGF-β receptor I phos‐
phorylates Smad 2 and 3 inducing their association with the common partner Smad 4, and then they translocate into
the nucleus, where they control the expression of TGF-β-responsive genes, such as that encoding integrin-linked kin‐
ase (ILK). The activation of up-regulated ILK by β1 integrins results in strong phosphorylation of Akt and glycogen syn‐
thase kinase-3 (GSK-3). Phosphorylated-Akt triggers NF-kB activation, which in turn induces the expression of Smad 7,
an inhibitory Smad molecule that interferes with the phosporylation of Smad 2 and 3, and of snail, a key regulator of
MMT. The transcription factor snail regulates MMT by inhibiting the expression of E-cadherin, and by inducing growth
arrest and survival, which confer selective advantage to migrating trans-differentiated cells. The phosphorylation of
GSK-3 by ILK results in its inhibition and subsequent stabilization of β-catenin, released from the adherens junction,
and of AP-1. Stabilized b-catenin, in conjunction with Lef-1/Tcf, may per se induce MMT, and AP-1 activates MMP-9
expression inducing the invasion of ECM. One of the main Smad-independent signalling cascades triggered by TGF-β
receptor I ligation, includes the RhoAp160ROCK pathway that regulates cytoskeleton remodelling and cellular migra‐
tion/ invasion. In addition, RhoA induces the expression of α-SMA in a ROCK-independent manner. Another signal
transduction stimulated by TGF-β is the H-Ras/Raf/ ERK pathway, which is also necessary for the induction of snail ex‐
pression and MMT.
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measured by using standard procedures. Patients whose drainage contained nonepithelioid
mesothelial cells had greater serum VEGF levels than those with epithelial-like mesothelial
cells in their effluent. VEGF production ex vivo by effluent mesothelial cells correlated with
serum VEGF level. In addition, Cr-MTC correlated with VEGF levels in culture and serum. Cr-
MTC also was associated with mesothelial cell phenotype. VEGF expression in stromal cells,
retaining mesothelial markers, was observed in peritoneal biopsy specimens from high-
transporter patients. These results suggest that mesothelial cells that have undergone epithe‐
lial-to-mesenchymal transition are the main source of VEGF in PD patients and therefore may
be responsible for a high peritoneal transport rate [3].
In a clinical study performed by our group, we studied the peritoneal anatomical changes
during the first months on PD, and to correlate them with peritoneal functional parameters.
We studied 35 stable PD patients for up to 2 years on PD, with a mean age of 45.37 years.
Seventy-four percent of patients presented loss of the mesothelial layer, 46% fibrosis and 17%
in situ evidence of MMT (submesothelial cytokeratin staining), which increased over time. All
patients with MMT showed myofibroblasts, while only 36% of patients without MMT had
myofibroblasts. The myofibroblasts represent a dynamic population of cells showing func‐
tional and phenotypic diversity. During the last years, numerous different molecules have
been reported to be expressed by tissue fibroblasts including peritoneal ones [10]. The origin
of tissue fibroblasts has been largely overlooked, so that their lineage is not fully elucidated.
There is now evidence supporting that fibro-myofibroblasts might originate from different
sources. Firstly, they may differentiate from resident tissue stem cells or fibroblasts. Secondly,
they can originate from nearby epithelial cells through a process known as MMT. Finally, the
bone marrow and circulating cells may be responsible for the production of fibro-myofibro‐
blasts circulating in the blood stream to their final tissue destination [33].
In PD, emergent evidence points that fibroblasts may arise from local conversion of epithelial
cells by MMT or from CD34 + cells (fibrocytes) of the bloodstream after being recruited from
bone marrow. In the case of renal fibrosis models, it has been shown that 36% of new fibroblasts
derive from MMT, 15% from bone marrow and the rest comes from local proliferation of
resident fibroblasts. In PD-related fibrosis, we have demonstrated the expression of mesothe‐
lial markers in stromal spindle-like cells, suggesting that they stemmed from local conversion
of MC. In contrast, we did not observe a significant contribution of CD34+ cells from bone
marrow to the submesothelial fibroblast population in the fibrotic peritoneal tissue [33].
In regard to angiogenesis, the number of peritoneal vessels did not vary when we compared
different times on PD. Vasculopathy was present in 17% of the samples. Functional studies
were used to define the peritoneal transport status. Patients in the highest quartile of mass
transfer area coefficient of creatinine (Cr-MTAC) showed significantly higher MMT prevalence
but similar number of peritoneal vessels. In the multivariate analysis, the highest quartile of
Cr-MTAC remained as an independent factor predicting the presence of MMT after adjusting
for fibrosis [34]. These findings indicate that MMT is a frequent morphological change in the
peritoneal membrane. These myofibroblastic cells with submesothelial localization may arise
from local conversion of MC during the repair responses and the high solute transport status
is associated with MMT.
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5. Are MMT, SPS and EPS part of the same process?
From MMT to SPS. Peritoneal fibrosis (or sclerosis) is a term that comprises a wide spectrum
of peritoneal structural alterations, ranging from mild inflammation to severe sclerosing
peritonitis and its most complicated manifestation, encapsulating peritonitis sclerosis (EPS) [6,
35, 36]. Simple sclerosis (SS), an intermediate stage of peritoneal fibrosis, is the most common
peritoneal lesion found in the patients after few months on PD, and could represent the initial
phase of sclerosing peritonitis syndrome (SPS). Rubin et al [5] described a normal thickness of
the peritoneum of 20 μm, but after a few months on PD could reach up to 40 μm (SS). The SP
is a progressive sclerosis that is characterized by a dramatic thickening of the peritoneum (up
to 4000 μm) and is accompanied by inflammatory infiltrates, calcification, neo-vascularization
and dilatation of blood and lymphatic vessels, being the thickening the most commonly used
pathological criterion for differential diagnosis [6, 35, 36].
The importance of establishing a connection between MMT, SPS and EPS is the potential
therapeutic and preventive effect of blocking this axis. Also emerging evidence suggests that
partial or total blockage of the MMT prevents early stages of PM fibrosis and angiogenesis and
preserves the PM function. Moreover, current studies show TGF-β is probably the most
important molecule in the PM failure development, so act on a single molecule, the TGF-β,
facilitates therapeutic approach. In fact we have shown that blockade of TGF-β significantly
attenuated PM failure induced by PD fluids.
One of the biggest problems to establish the definitive connection between SPS and EPS is that
the EPS animal model has not been fully and properly developed. While in our mice PD model
in 4 or more weeks reaches the typical changes induced by PD fluids on humans, the peritoneal
fibrosis model with chlorhexidine results artificial and extremely aggressive. The experimental
development of an appropriate EPS model is mandatory. Possibly the most appropriate EPS
mice model would be to maintain long-term (months) in PD according to our model of SPS.
Once accepted this limitation, the current data suggest that MMT and SPS are part of the
process. We have analyzed serially PM pieces of mice in PD at baseline, 15 and 30 days and
we found a linear correlation between time on PD, the thickness of the PM and the number of
MCs cytokeratin (+) and FSP-1 (+) in the area submesothelial. This phenomenon was accom‐
panied by progressive loss of the mesothelial monolayer which indicates an important
participation of the MMT in the development of peritoneal fibrosis (our unpublished results).
Using a TGF-β adenovirus model, we found early MMT at 4 day after stimuli intraperitoneal
injection that was correlated with PM fibrosis [14]. Similar finding was found by others [15].
Clinically, in MCs serially isolated and cultured from PD effluents, the MMT was present
progressively over time in PD and is associated with solute transport disorders and ultrafil‐
tration failure [37]. In PM biopsies from 35 PD stable patients performed during the first 2
years on PD, we demonstrated that the first morphological change in peritoneum that appears
as a consequence of PD is submesothelial thickening partially caused by the MMT. This
phenotype change is associated with an increase in peritoneal solute transport independent of
the number of capillaries present in the tissue [1, 3]. Reaching this point, the following
questions arise, as follows: could have peritoneal fibrosis without MMT?, or more specifically,
MMT and Peritoneal Membrane Failure
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could have MMT without the participation of TGF-β?. Experimental data by us [14] and others
[15] indicate that blocking MMT in different degrees result in a significantly attenuation of
structural and functional changes of PM. Using the adenovirus (TGF-β) and our PD mice
model, the double submesothelial staining for cytokeratin (+) and FSP1 (+) was positive in
approximately 37% of activated fibroblasts, indicating its epithelial origin [14]. However, the
peritoneal fibrosis is inhibited in more than 50% indicating that direct inhibition of TGF-β with
anti-TGF-β peptides inhibited other effects of this molecule as the activation of regional
fibroblasts. Promising results have also obtained acting on immune system [38], on AGEs
accumulation [39] or on renin-angiotensin system (ACE, AR-II, Paricalcitol) and BMP-7 which
also modulate directly or indirectly the TGF-β [40]. These arguments lead us to conclude that
TGF-β is a key in the initiation and possibly perpetuation of an uncontrolled MMT, which
leads to fibrosis and SPS.
From SPS to EPS. The next question is as follows: at which point the SPS becomes an irrever‐
sible process to become EPS? The “two-hit” hypothesis explains the EPS as the result of the
PD injury. Two factors are required for the onset of EPS: a predisposing factor, such as
peritoneal deterioration from persistent injury caused by peritoneal dialysis (the first “hit”),
and an initiating factor, such as inflammatory stimuli superimposed on the chronically injured
peritoneum (the second “hit”). Peritoneal deterioration (consisting of mesothelial denudation,
interstitial fibrosis, vasculopathy, and angiogenesis) leads to an increased tendency toward
plasma exudations that contain fibrin and coagulation factors. The fibrins in the exudates
contribute to the intestinal adhesions and formation of fibrin capsule. Inflammatory stimuli
caused by infectious peritonitis are superimposed on the damaged peritoneum and act as an
initiating factor to trigger the onset of EPS. Inflammatory cytokines also induce activation and
proliferation of the peritoneal fibroblasts, promoting peritoneal fibrosis and intestinal adhe‐
sions. The relationship between the extent of the first and second “hits” can be demonstrated.
The extent of peritoneal damage (the first “hit”) increases with the duration of peritoneal
dialysis [41, 42].
The onset of EPS depends on the total intensity of both lesions: peritoneal damage and
inflammatory stimuli. For the onset of EPS, the total intensity must be greater than a given
threshold. The extent of the inflammatory stimuli (the second “hit”) are required for the onset
of EPS [41, 42].
In both cases (acute and chronic peritoneal injury), the TGF-β is activated with subsequent
initiation and perpetuation of MMT and its deleterious effects (fibrosis, angiogenesis, etc.).
However, it is very difficult to establish the point of no return in peritoneal lesions clinically
because patients with type-I PM failure usually recover functionality and possibly tissue
damage with rest peritoneal [43]. In experimental animals, data about fibrosis reversibility are
not available. Unfortunately, the initial degree of PM fibrosis has been determined in very few
cases (peritoneal biopsies not available). Finally a genetic component cannot be ruled [44, 45].
From MMT to EPS. In both, experimental animals [14, 46] and human peritoneal biopsies from
patients within 2 years in PD [34], it seems clear that MMT is an early phenomenon able to
determine the degree of peritoneal fibrosis and the future of the PM. But no information about
MMT in patients with long term in PD or diagnosis of EPS is available. It is possible that MMT
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may be an initial phenomenon and few signs of it are in severe stages of fibrosis. However, in
bridles and postsurgical adhesions, we have found MMT signs (unpublished data by us), and
Bowel adherences may represent an intermediate degree between the SPS and EPS (our
unpublished data by us), which encourages to conduct studies aimed to find MMT peritoneum
with EPS.
These findings represent important evidence linking both processes, but indirect evidence may
also be marked. In human studies [3, 11] and in experimental animals [47], our studies
demonstrated a direct relationship between MMT and time on PD. Similarly, the several
studies showed a parallel between EPS and time on PD [2, 48]. Another important fact is that
peritoneal function studies also show a parallel between high frequency ofMMT ofMCs, high
Cr-MTC, and low ultrafiltration. Indeed we observed a higher frequency of mesothelial
fibroblastoid phenotype in patients with type Cr-MTC >11 mL/min [3]. Furthermore, as is well
known, patients with EPS even displayed these with SPS showed similar functional PM
deterioration [35, 49, 50]. Another indirect association between these two events is peritonitis.
Yañez-Mo and coworkers [11] found that the frequency of nonepithelioidMCwas associated
with episodes of peritonitis, thismeans that peritonitis leads to theMMT. In the case of theEPS,
there are some studies in the literature that correlate it with peritonitis events. Previous studies
suggest that peritonitis may predispose to EPS, especially if this is caused by Staphylococcus
aureus, fungi, and/or Pseudomonas [9, 51]. There is also an association between persistent
infections such as tuberculosis peritonitis and EPS [52]. Although peritonitis and EPS are
highly associated in several studies it is also known that, especially in a long-term case, EPS
may occur without peritonitis. Moreover, patients that have suffered from more events of
peritonitis have a higher incidence of MMT and EPS, which suggest again that these processes
are related. Finally, we have analyzed more than 10 peritoneal biopsies from patients with EPS
where we had found a significant amount of mesothelial cells (CK +) in the peritoneal subme‐
sothelial area, which indicates that despite the significant denudation of the peritoneal MCs
monolayer.
6. The MMT as therapeutic target
Based on the concept, that MMT, fibrosis and angiogenesis may be part of the same process of
peritoneal membrane failure, therapeutic approaches may be addressed to prevent either
MMT of the MC or its deleterious effects such as ECM synthesis and/or VEGF production. In
this context, in vitro and ex vivo cultures of MC may be useful for testing pharmacological agents
with potential effects on MMT of the MC. Two molecules with expected preventive effect on
the MMT of MC are hepatocyte growth factor (HGF) and bone morphogenic protein-7 (BMP-7).
It has been demonstrated that these molecules are able to inhibit and reverse MMT and renal
fibrosis in animal models. [53-54]. Other strategies that would open new avenues of therapeutic
intervention to prevent or reverse MMT of MC may include the inhibition of ILK, RhoA-ROCK
or Akt-mediated signaling cascades [25-33, 55]. In this context, the administration of the ROCK
inhibitor Y-27632 resulted in suppression of α-SMA expression and renal interstitial fibrosis
in a mouse model of ureteral obstruction. [55]
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We performed our studies using testing different drugs or anti-MMT strategies. We have
developed a PD mouse model, this consist in the intra-abdominal catheter implantation with
a subcutaneous chamber localized in the top of mouse back. After, we injected a daily intra-
peritoneal injection of PD solution (1.5-2 mL) at least for 4 weeks. In-vitro we used MCs isolated
from omentum and from PD peritoneal effluent. We managed to inhibit the MMT and its
adverse effects from using rBMP7 [40]. With Rapamycin got a specific inhibition of fibrosis
and the vessels formation specifically lymphatic vessels (56, 57, our unpublished results).
Rosiglitazone showed an inhibitory effect on the accumulation of submesothelial AGEs, also
anti-inflammatory action mediated by T-cells was observed [39]. Similarly, celecocib inhibited
the peritoneal fibrosis by an anti-cox2 effect [38]. MMT also was prevented by tamoxifen. This
drug inhibited the peritoneal fibrosis and increased MCs fibrinolytic capacity [47]. Clinically,
tamoxifen also improved survival in patients diagnosed of EPS [58]. Paricalcitol acted on
Figure 4. Therapeutic approach to MMT. MMT in vivo results from integrated signals that are induced by multiple
stimuli. These include elevated glucose and glucose degradation products (GDP) and concentration of PD fluids, which
through the formation of advanced glycation-end products (AGE) stimulate the transdifferentiation of MC. The forma‐
tion of AGE may also be due to the uremic status of the PD patients. The low pH of the dialysates and the mechanical
injury during PD fluid exchanges may cause tissue irritation and contribute to chronic inflammation of the perito‐
neum, which promote MMT. Episodes of bacterial or fungal infections or hemoperitoneum cause acute inflammation
and upregulation of cytokines and growth factors such as TGF-β, IL-1, fibroblast growth factor-2 (FGF-2), TNF-α, and
angiotensin-II, among others, which are strong inducers of MMT. The therapeutic strategies may be designed either to
prevent or to reverse the MMT itself or to treat its effects such as cellular invasion, fibrosis, or angiogenesis. The dia‐
gram illustrates six steps related to the MMT process of the MC that can be clinically managed, alone or in combina‐
tion, to prevent peritoneal membrane failure. The numbers represent the steps where different drugs or molecules
can act. 1: Tamoxifen, AGEs accumulation inhibitors (Rosiglitazone), BMP7 and HGF; 2: BMP7 and HGF; 3: Invasion In‐
hibitors (MMPs blocked); 4: Antifibrotic i, e: rapamycin; 5: Tamoxifen and heparin; 6: Angiogenesis inhibitors (rapamy‐
cin, inhinitors CO2, etc.)
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smads cascade inhibiting the MMT (our unpublished results). Finally, we were able to inhibit
specifically TGF-β with anti-TGF-β specific peptides demonstrating the role of TGF-β in the
initiation and perpetuation of MMT [14]. In this context, other promising substances are
pentoxifylline, dipyridamole, and emodin [59-61]. Figure 4 summarizes the sites where we
may act by blocking the MMT or adverse effects. Some of these drugs and / or therapeutic
strategies have been described by our group.
7. Conclusion
Recent findings suggest that in the peritoneum new fibroblast-like cells arise from local
conversion of MMT during the repair responses that take place in long-term PD. These trans-
differentiated MC may invade the submesothelial tissue and may contribute to peritoneal
fibrosis and angiogenesis, which ultimately lead to peritoneal membrane failure. MMT
appears as the central point in the pathogenesis of peritoneal damage associated to PD. Current
data support a connection between MMT and SPS. However, the jump from SPS to EPS and
the connection between MMT and EPS have not been fully established. MMT can be a
therapeutic target the blockade of which could benefit especially in initial stages of the process.
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